Most engaging posts mentioning stocks from @BioStocks over the last 72 hours.
03/23/23
$MRNA and $GBIO announce Strategic Collaboration to Develop Non-Viral Genetic Medicines.
Generation Bio to receive $40M upfront plus a $36M equity investment from Moderna
03/24/23
$ETNB $275M offering.
16.93M shares at $16.25/share
03/23/23
$SQ @HindenburgRes out with short report
03/24/23
RT @PropThinker: $AFMD combo 24 data could spill over to Q3. Even with delay, could be light on efficacy. From conference call:
“So we wi…
03/24/23
$ALLR 1-for-35 Reverse Split
03/24/23
$ASLN TREK-AD Phase 2b study of Eblasakimab fully enrolled.
Topline data early July.
03/24/23
$PTCT Stuart Peltz to Retire as CEO.
03/24/23
$COIN downgraded to Underperform at TD Cowen. PT $36
03/23/23
$INZY upgraded to Buy at Jefferies. PT $6
03/23/23
$AFMD AFM13 combination with AB-101 NK cells: On track for IND filing in 1H'23 and study initiation in 2023
AFM13 monotherapy REDIRECT data: Oral presentation at #AACR23
AFM24: Data from the three ongoing studies to be presented at conferences in Q2 or Q3
Cash €190.3M
03/23/23
$AMC resumed with a Sell at Citi. PT $1.60
03/24/23
$LPTX issued ~ 137K shares of Series X convertible preferred stock in connection with the acquisition of Flame Biosciences.
If approved at the annual meeting in June, the preferred stock will convert into 136.8M shares of common stock. 😬
03/23/23
$BIIB Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
https://t.co/tsUC3hnuD3
03/23/23
$ABBV Risankizumab Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
03/23/23
$MNPR Validive Phase 2b/3 VOICE Trial Go/No-Go Interim Readout by End of Next Week
03/23/23
$GBIO resumes. ↑ 35%
03/24/23
$INCY FDA issues CRL for Ruxolitinib XR tablets.
03/23/23
$CDTX raised ~ $9M via ATM in Q1.
03/24/23
Carl Icahn open letter to $ILMN shareholders.
Icahn to Commence Investigation into Value Destruction by Illumina’s Board.
https://t.co/HJ2xec2Uei $ILMN